This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (140)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Simone E. Düby, MD; George C. Cotzias, MD; Paul S. Papavasiliou, MD; William H. Lawrence, MD

Arch Neurol. 1972;27(6):474-480.

Abstract
Among 31 patients with parkinsonism three investigations were performed by injecting apomorphine hydrochloride or placebo: (1) to 17 patients with or without orally administered levodopa, (2) to 14 patients receiving levodopa during episodes of tremor, hypokinesia or involuntary movements, and 3 to 10 patients three to 6 times a day for 2 to 43 days. With or without levodopa, apomorphine diminished tremor and rigidity. It decreased bradykinesia in patients receiving levodopa. The respective side effects were not additive: the "awakening effect", involuntary movements, and nausea induced by levodopa were antagonized by apomorphine, whereas the sedative effect and the nausea of apomorphine were antagonized by levodopa. The dichotomy between synergistic and antagonistic effects may be explained by the molecule of apomorphine, part of which resembles dopamine and the other resembles phenylethylamine, which can displace neurotransmitters from cellular sites.

Author Affiliations
Upton, Long Island, NY

From the Medical Research Center, Brookhaven National Laboratory, Upton, Long Island, NY.

Footnotes
Accepted for publication June 16, 1972.

Reprint requests to Hospital of the Medical Research Center, Brookhaven National Laboratory, Upton, NY 11973 (Dr. Cotzias).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Literature review: Intermittent subcutaneous apomorphine therapy in Parkinson's disease
Factor
Neurology 2004;62:S12-S17.
ABSTRACT | FULL TEXT  

Practical considerations in the use of apomorphine injectable
Bowron
Neurology 2004;62:S32-S36.
ABSTRACT | FULL TEXT  

A Randomized, Double-blind, Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events
Dewey et al.
Arch Neurol 2001;58:1385-1392.
ABSTRACT | FULL TEXT  

Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease
Colzi et al.
J. Neurol. Neurosurg. Psychiatry 1998;64:573-576.
ABSTRACT | FULL TEXT  

Effects of Dopamine Agonists and Antagonists in Tourette's Disease
Feinberg and Carroll
Arch Gen Psychiatry 1979;36:979-985.
ABSTRACT  

Treatment of Parkinsonism With N-n-Propyl Norapomorphine and Levodopa (With or Without Carbidopa)
Papavasiliou et al.
Arch Neurol 1978;35:787-791.
ABSTRACT  

Modification of Tardive Dyskinesia and Spasmodic Torticollis by Apomorphine: Possible Role of Dopamine Autoreceptors
Tolosa
Arch Neurol 1978;35:459-462.
ABSTRACT  

Apomorphine Hydrochloride-Induced Improvement in Huntington's Chorea: Stimulation of Dopamine Receptor
Corsini et al.
Arch Neurol 1978;35:27-30.
ABSTRACT  

Modification of the Actions of Some Neuroactive Drugs by Growth Hormone
Tang and Cotzias
Arch Neurol 1976;33:131-134.
ABSTRACT  

Five Years' Treatment of Parkinson's Disease with Levodopa: Therapeutic Results and Survival of 100 Patients
SWEET and McDOWELL
ANN INTERN MED 1975;83:456-463.
ABSTRACT  

Treatment of "On-Off Effect" With A Dopa Decarboxylase Inhibitor
Sweet et al.
Arch Neurol 1975;32:560-563.
ABSTRACT  

Diphenylhydantoin: Blocking of Levodopa Effects
Mendez et al.
Arch Neurol 1975;32:44-46.
ABSTRACT  

Parkinson Disease Treated With a Suspected Dopamine Receptor Agonist
Chase et al.
Arch Neurol 1974;30:383-386.
ABSTRACT  

Central Monoamine Metabolism in Man: Effect of Putative Dopamine Receptor Agonists and Antagonists
Chase
Arch Neurol 1973;29:349-351.
ABSTRACT